Summary
It is possible today to design innovative vaccines that will provide a tailored immune response adapted to the challenges
posed by the pathogen and the target population.
Novel adjuvant systems have been developed and used in various applications. They are fundamental for the development of new
and more effective vaccines for very challenging diseases. Vaccine formulation using adjuvant systems and the numerous benefits
of these compared with classical adjuvantation or non-adjuvanted formulation have promoted research in new areas of application
beyond prevention, such as therapeutic vaccines and chronic disorders. The ASCI approach is at an advanced stage of research
and may bring new hope in the fight against cancer.
Acknowledgements
We would like to acknowledge Diane Lejeune (GSK Biologicals) for having extensively contributed to the review of the manuscript,
Marleen Mergaerts and Markus Voges (GSK Biologicals) for assistance in preparing the manuscript, and Géraldine Drevon and
Luise Kalbe (GSK Biologicals) for editorial assistance and coordination of manuscript development.
Trademarks
Prepandrix and Cervarix are trademarks of the GlaxoSmithKline group of companies. Gardasil is a registered trademark of Merck
& Co, Inc.
Conflict of Interest Statement
Nathalie Garçon, Alberta Di Pasquale, and Philippe Monteyne are all employees of GSK Biologicals.
NATHALIE GARÇON, PhD, is the vice president and head of the Global Adjuvant Center for Vaccines, ALBERTA DI PASQUALE, PhD, is the director of global medical affairs, adjuvants, and PHILIPPE MONTEYNE, MD, PhD, is the senior vice president of global vaccine development, all at GlaxoSmithKline Biologicals, Wavre, Belgium, +32 (0)1
085 8856, nathalie.garcon@gskbio.com
|
